Research Paper Volume 15, Issue 16 pp 8325—8344

Construction and validation of cuproptosis-related lncRNA prediction signature for bladder cancer and immune infiltration analysis

Hanrong Li1, , Huiming Jiang2, , Zhicheng Huang2, , Zhilin Chen2, , Nanhui Chen2, ,

  • 1 Department of Extracorporeal Shock Wave Lithotripsy, Meizhou People’s Hospital (Huangtang Hospital), Meizhou 514031, China
  • 2 Department of Urology, Meizhou People’s Hospital (Huangtang Hospital), Meizhou 514031, China

Received: April 25, 2023       Accepted: July 10, 2023       Published: August 23, 2023
How to Cite

Copyright: © 2023 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Bladder cancer (BC) is a common urologic tumor with a high recurrence rate. Cuproptosis and long noncoding RNAs (lncRNAs) have demonstrated essential roles in the tumorigenesis of many malignancies. Nevertheless, the prognostic value of cuproptosis-related lncRNA (CRLs) in BC is still unclear. The public data used for this study were acquired from the Cancer Genome Atlas database. A comprehensive exploration of the expression profile, mutation, co-expression, and enrichment analyses of cuproptosis-related genes was performed. A total of 466 CRLs were identified using Pearson’s correlation analysis. 16 prognostic CRLs were then retained by univariate Cox regression. Unsupervised clustering divided the patients into two clusters with diverse survival outcomes. The signature consists of 7 CRLs was constructed using the least absolute shrinkage and selection operator (LASSO) Cox regression analyses. Survival curves and receiver operating characteristics showed the prognostic signature possessed good predictive value, which was validated in the testing and entire sets. The reliability and stability of our signature were further confirmed by stratified analysis. Additionally, the signature-based risk score was confirmed as an independent prognostic factor. Gene set enrichment analysis showed molecular alteration in the high-risk group was closely associated with cancer. We then developed the clinical nomogram using independent prognostic indicators. Notably, the infiltration of immune cells and expression of immune checkpoints were higher in the high-risk group, suggesting that they may benefit more from immunotherapy. In summary, the prognostic signature might effectively predict the prognosis and provide new insight into the clinical treatment of BC patients.


BC: Bladder cancer; BP: Biological processes; CC: Cellular component; CDF: Cumulative distribution function; CNV: Copy number variation; CRGs: Cuproptosis-related genes; CRLs: Cuproptosis-related lncRNAs; DCA: Decision curve analysis; GO: Gene ontology; GSEA: Gene set enrichment analysis; ICI: Immune checkpoint inhibitor; KEGG: Kyoto Encyclopedia of Genes and Genomes; LASSO: Least absolute shrinkage and selection operator; lncRNAs: Long noncoding RNAs; MF: Molecular function; OS: Overall survival; ROC: Receiver operating characteristic; ssGSEA: Single sample gene set enrichment analysis; TAC: Tricarboxylic acid; TCGA: The Cancer Genome Atlas.